详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Berberine in the treatment of ulcerative colitis: A possible pathway through Tuft cells

75| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE ◇ 预警期刊

作者：

单位： [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Integrated Tradit Chinese & Western Med,Wuhan 430030,Peoples R China [2]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Inst Integrated Tradit Chinese & Western Med,Wuhan 430030,Peoples R China [3]Sun Yat Sen Univ, Affiliated Hosp 6, Gastrointestinal & Anal Hosp, Dept Coloproctol, Guangzhou 510655, Peoples R China

出处：

DOI：

ISSN：

关键词： Berberine Ulcerative colitis Bitter taste receptor Tuft cell Intestinal stem cell

摘要：

Ulcerative colitis (UC) is an inflammatory bowel disease with complex pathogenesis, which is affected by genetic factors, intestinal immune status and intestinal microbial homeostasis. Intestinal epithelial barrier defect is crucial to the development of UC. Berberine, extracted from Chinese medicine, can identify bitter taste receptor on intestinal Tuft cells and activate IL-25-ILC2-IL-13 immune pathway to impair damaged intestinal tract by promoting differentiation of intestinal stem cells, which might be a potential approach for the treatment of UC.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

大类 | 2 区医学

小类 | 2 区药学 3 区医学：研究与实验

最新[2025]版：

大类 | 2 区医学

小类 | 2 区医学：研究与实验 2 区药学

JCR分区：

出版当年[2019]版：

Q1 PHARMACOLOGY & PHARMACY Q1 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q1 MEDICINE, RESEARCH & EXPERIMENTAL Q1 PHARMACOLOGY & PHARMACY

影响因子： 6.9 最新[2023版] 6.8 最新五年平均 4.545 出版当年[2019版] 4.392 出版当年五年平均 3.743 出版前一年[2018版] 6.53 出版后一年[2020版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Integrated Tradit Chinese & Western Med,Wuhan 430030,Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis (UC) [2]ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 [3]Stringent criteria for withdrawal of biologics in ulcerative colitis reply [4]Ulcerative colitis complicated with salmonella london infection: One case report [5]A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis [6]Expressions of E-cadherin, p120ctn, β-catenin and NF-κB in ulcerative colitis [7]Comprehensive analysis of key biomarkers, immune infiltration and potential therapeutic agents for ulcerative colitis [8]A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. [9]A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis [10]Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis